A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6-35 months

Vaccine

Volumn 28, Issue 38, 2010, Pages 6137-6144

  Esposito, Susanna ^a   Marchisio, Paola ^a   Ansaldi, Filippo ^b   Bianchini, Sonia ^a   Pacei, Michela ^a   Baggi, Elena ^a   Trabattoni, Daria ^a   Icardi, Giancarlo ^b   Principi, Nicola ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Children; Immunogenicity; Influenza; Influenza vaccine; Reactogenicity; Virosomal

Indexed keywords

GAMMA INTERFERON; INFLUENZA VACCINE; INTERLEUKIN 2; VIROSOME;

ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYTOKINE PRODUCTION; DECREASED APPETITE; DOSE TIME EFFECT RELATION; DRUG ANTIGENICITY; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INFANT; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE SWELLING; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SEROCONVERSION; SIDE EFFECT; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, VIRAL; CHILD, PRESCHOOL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION SCHEDULE; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; PROSPECTIVE STUDIES; VACCINES, VIROSOME;

EID: 77955663597     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.07.041     Document Type: Article

References (41)

1. Principi N., Esposito S. Are we ready for universal influenza vaccination in paediatrics?. Lancet Infect Dis 2004, 4:75-83.
2. Principi N., Esposito S. Prevention or control of influenza in the pediatric population. Emerg Infect Dis 2004, 10:574-580.
3. Esposito S., Principi N. The rational use of influenza vaccines in healthy children and children with underlying conditions. Curr Opin Infect Dis 2009, 22:244-249.
4. Neuzil K.M., Mellen B.G., Wright P.F., Mitchel E.F., Griffin M.R. The effect of influenza on hospitalizations, outpatients visits, and courses of antibiotics in children. N Engl J Med 2000, 342:225-231.
5. Heikkinen T., Silvennoinen H., Peltola V., Ziegler T., Vainionpaa R., Vuorinen T., et al. Burden of influenza in children in the community. J Infect Dis 2004, 190:1369-1373.
6. Poehling K.A., Edwards K.M., Weinberg G.A., Szilagyi P., Staat M.A., Iwane M.K., et al. The underrecognized burden of influenza in young children. N Engl J Med 2006, 355:31-40.
7. Esposito S., Marchisio P., Principi N. The global state of influenza in children. Pediatr Infect Dis J 2008, 27(11 Suppl.):S149-S153.
8. Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009; 58 (RR-8):1-52.
9. Rapola S. National immunization program in Finland. Int J Circumpolar Health 2007, 66:382-389.
10. Jefferson T., Tivetti A., Harnden A., Di Pietrantonj C., Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008, CD004879.
11. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356:685-696.
12. MedImmune LLC. FluMist Influenza Vaccine Live, Intranasal Spray; 2009-2010 Formula. Package insert.
13. Palache A.M., Beyer W.E.P., Sprenger M.J.W., Völker R., Sprenger M.J., Masurel N. Antibody response after influenza immunization with various vaccine doses: a double-blind, placebo-controlled, multi-centre, dose-response study in elderly nursing-home residents and young volunteers. Vaccine 1993, 11:3-7.
14. De Donato S., Granoff D., Minutello M., Lecchi G., Faccini M., Agnello M., et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 1999, 17:23-24.
15. Keitel W.A., Atmar R.L., Cate T.R., Petersen N.J., Greenberg S.B., Ruben F., et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Inter Med 2006, 166:1121-1127.
16. Couch R.B., Winokur P., Brady R., Belshe R., Chen W.H., Cate T.R., et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007, 25:7656-7663.
17. Engler R.J., Nelson M.R., Klote M.M., VanRaden M.J., Huang C.Y., Cox N.J., et al. Half- vs full-dose trivalent influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med 2008, 168:2405-2414.
18. Arnou R., Icardi G., De Decker M., Ambrozaitis A., Kazek M.P., Weber F., et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 2009, 27:7304-7312.
19. Kunzi V., Klap J.M., Seiberling M.K., Herzog C., Hartmann K., Kürsteiner O., et al. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration. Vaccine 2009, 27:3561-3567.
20. Cools H.J., Gussekloo J., Remmerswaal J.E., Remarque E.J., Kroes A.C. Benefits of increasing the dose of influenza vaccine in residents of long-term facilities: a randomized placebo-controlled trial. J Med Virol 2009, 81:904-914.
21. Palache A.M., Beyer W.E.P., Osterhaus A.D.M.E. Influenza vaccine dosages. Vaccine 2008, 26:2305-2306.
22. Chiu S.S., Malik Peiris J.S., Chan K.H., Wong W.H., Lau Y.L. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. Pediatrics 2007, 119:1076-1082.
23. Sugimura T., Ito Y., Tananari Y., Ozaki Y., Maeno Y., Yamaoka T., et al. Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination. Vaccine 2008, 26:2700-2705.
24. Vesikari T., Pellegrini M., Karvonen A., Groth N., Borkowski A., O'Hagan D.T., et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009, 28:563-571.
25. Kanra G., Marchisio P., Feiterna-Sperling C., Gaedicke G., Lazar H., Durrer P., et al. Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children. Pediatr Infect Dis J 2004, 23:300-306.
26. Esposito S., Marchisio P., Bosis S., Lambertini L., Claut L., Faelli N., et al. Clinical and economic impact of influenza vaccination on healthy children aged 2-5 years. Vaccine 2006, 24:629-635.
27. Nolan T., McVernon J., Skeljo M., Richmond P., Wadia U., Lambert S., et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in infants and children. JAMA 2010, 303:37-46.
28. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Gittleson C., Bennet J., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009, 361:2405-2413.
29. Ansaldi F., Bacilieri S., Durando P., Sticchi L., Valle L., Montomoli E., et al. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 2008, 26:1525-1529.
30. Setti M., Fenoglio D., Ansaldi F., Filaci G., Bacilieri S., Sticchi L., et al. Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients. Vaccine 2009, 27:3367-3372.
31. Tanzi E., Esposito S., Bojanin J., Amendola A., Trabattoni D., Pariani E., Pinzani R., et al. Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T cell activation in HIV-infected children receiving highly active antiretroviral therapy. J Med Virol 2006, 78:440-445.
32. European Agency for the Evaluation of Medicinal Products (EMEA) - Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96). London, March 12, 1997.
33. Viganò A., Zuccotti G.V., Pacei M., Erba P., Castelletti E., Giacomet V., et al. Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy. J Acquir Immune Defic Syndr 2008, 48:289-296.
34. Kelly H., Attia J., Andrews R., Heller R.F. The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over. Vaccine 2004, 22:2192-2198.
35. Laupacis A., Sackett D.L., Roberts R.S. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988, 318:1728-1733.
36. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289:179-186.
37. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Bridges C.B., Cox N.J., et al. Influenza-associated hospitalization in the United States. JAMA 2004, 292:1333-1340.
38. Walter E.B., Neuzil K.M., Zhu Y., Fairchok M.P., Gagliano M.E., Monto A.S., et al. Influenza vaccine immunogenicity in 6 to 23-months-old children: are identical antigens necessary for priming?. Pediatrics 2006, 118:e570-e578.
39. Mitchell D.K., Ruben F.L., Gravenstein S. Immunogenicity and safety of inactivated influenza vaccine in young children in 2003-2004. Pediatr Infect Dis J 2005, 10:925-927.
40. Englund J.A., Walter E.B., Fairchok M.P., Monto A.S., Neuzil K.M. A comparison of 2 influenza vaccine schedules in 6- to 23-months-old children. Pediatrics 2005, 1039-1047.
41. Esposito S., Marchisio P., Droghetti R., Lambertini L., Faelli N., Bosis S., et al. Influenza vaccination coverage among children with high-risk medical conditions. Vaccine 2006, 24:5251-5255.